These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11791126)

  • 21. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
    de Jong PC; Blijham GH
    Neth J Med; 1999 Aug; 55(2):50-8. PubMed ID: 10474272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C
    Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
    Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aromatase inhibitors in breast cancer therapy.
    Buzdar AU
    Clin Breast Cancer; 2003 Nov; 4 Suppl 2():S84-8. PubMed ID: 14667279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
    Clemons M; Coleman RE; Verma S
    Cancer Treat Rev; 2004 Jun; 30(4):325-32. PubMed ID: 15145507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aromatase inhibitors in breast cancer: an update.
    Lake DE; Hudis C
    Cancer Control; 2002; 9(6):490-8. PubMed ID: 12514567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neoadjuvant endocrine therapy for locally advanced breast cancer].
    Viola G; Sergi D; Conti F; Lopez M
    Clin Ter; 2007; 158(5):441-52. PubMed ID: 18062352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
    Brodie AH; Mouridsen HT
    Am J Clin Oncol; 2003 Aug; 26(4):S17-26. PubMed ID: 12902873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Aromatase inhibitors: a review of clinical trials].
    Kerbrat P; Lefeuvre C
    Bull Cancer; 2000 Dec; 87 Spec No():31-39. PubMed ID: 11250606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
    Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
    Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
    Buzdar AU; Vergote I; Sainsbury R
    Breast J; 2004; 10(3):211-7. PubMed ID: 15125747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    Dranitsaris G; Verma S; Trudeau M
    Am J Clin Oncol; 2003 Jun; 26(3):289-96. PubMed ID: 12796603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
    Nabholtz JM; Reese DM
    Breast Cancer; 2001; 8(4):305-9. PubMed ID: 11791122
    [No Abstract]   [Full Text] [Related]  

  • 40. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.